Humana’s chief legal officer trims holding by 20.1% in a stock sale (NYSE: HUM)

What happened

Joseph C. Ventura, chief legal officer of Humana Inc (NYSE: HUM), sold 5,495 shares on Nov. 9 at a weighted average $433.85. The sale brought in about $2.38 million and left Ventura with 21,910 shares, a count that includes 16,568 restricted stock units.

Ventura also gave 437 shares to charity effective the same day and received no value in return. That left 21,473 shares held directly. Another 293 shares are held for Ventura's benefit in the Humana Retirement Savings Plan. Ventura signed the Form 4 on Nov. 11.

Key numbers

Metric	Latest	Change	Source
Shares sold	5,495 shares		SEC Form 4
Weighted average sale price	$433.85		SEC Form 4
Total sale value	$2.38 million		SEC Form 4
Share of pre-trade holding sold	20.1%		Calculated from SEC Form 4
Direct shares after sale and gift	21,473 shares		SEC Form 4

Read more: Humana (HUM) company research

Why it matters

OptimistFi's calculation shows the shares sold were 20.1% of the 27,405 shares held before the trade. That is a sizable slice of the position, though the charitable gift is a separate disposal and not a sale.

The filing splits Ventura's position into several pieces: shares held directly, restricted stock units that count toward that direct total, shares held through the Humana Retirement Savings Plan, and option grants. Only the sale and the charitable gift reduced the direct share count on Nov. 9. Ventura still holds the units and options, so the position keeps exposure to Humana's share price.

Ventura also holds five option grants under Humana's 2019 stock incentive plan. Each covers between 3,932 and 6,572 shares, with exercise prices from $350.79 to $510.24 and expiry dates running from Feb. 24, 2027 to Feb. 21, 2031.

OptimistFi has argued that Humana is attractive only if underwriting results and operating cash flow recover from recent reserve and medical-cost pressure. The sale leaves that case unchanged.

The holdings Ventura keeps, which include the restricted stock units and the options, make it hard to read this sale as a verdict on Humana's operating outlook.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

Humana's next quarterly report is the test of the investment case. Better underwriting results and stronger operating cash flow would support it, while further reserve or medical-cost pressure would weaken it.

More from OptimistFi

• HUM stock: research and coverage of Humana
• Stock research on every company OptimistFi covers

From OptimistFi Perps